» Articles » PMID: 2521301

Cellular Targets for Transformation by the Adenovirus E1A Proteins

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 1989 Jan 13
PMID 2521301
Citations 315
Authors
Affiliations
Soon will be listed here.
Abstract

Three cellular proteins, including species of 300,000 daltons and 107,000 daltons as well as p105-RB, the product of the retinoblastoma susceptibility gene, stably interact with the adenovirus E1A proteins. To help determine the functional basis of these interactions, the regions of E1A that participate in these interactions were mapped using a series of deletion mutants. The 300,000 dalton and the 107,000 dalton proteins interacted with sequences within amino acids 1 to 76 and 121 to 127, respectively. Interaction with the third cellular protein, p105-RB, required the presence of sequences from two noncontiguous regions of the E1A polypeptide chain, amino acids 30 to 60 and 121 to 127. The regions of E1A that are required for these interactions coincided precisely with the regions of E1A that are required for its transforming function. These results suggest that the interactions with these cellular proteins are fundamental to the transforming activity of E1A.

Citing Articles

Dysregulation of the p300/CBP histone acetyltransferases in human cancer.

Xu L, Xuan H, Shi X Epigenomics. 2025; 17(3):193-208.

PMID: 39929233 PMC: 11812348. DOI: 10.1080/17501911.2024.2447807.


An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumor targeting.

Wienen F, Nilson R, Allmendinger E, Peters S, Barth T, Kochanek S Mol Ther Oncol. 2025; 32(4):200909.

PMID: 39758252 PMC: 11699628. DOI: 10.1016/j.omton.2024.200909.


Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.

Dawson L, Alshawabkeh M, Schroer K, Arakrak F, Ehrhardt A, Zhang W Eng Microbiol. 2024; 4(1):100140.

PMID: 39628785 PMC: 11611009. DOI: 10.1016/j.engmic.2024.100140.


Potential Therapeutic Targets for the Treatment of HPV-Associated Malignancies.

Lu Z, Haghollahi S, Afzal M Cancers (Basel). 2024; 16(20).

PMID: 39456568 PMC: 11506301. DOI: 10.3390/cancers16203474.


Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.

Ramos-Gonzalez M, Tarique M, Batra L, Arguc F, Garza-Morales R, Shirwan H Vaccines (Basel). 2024; 12(3).

PMID: 38543974 PMC: 10974162. DOI: 10.3390/vaccines12030340.